Experimental HIV immune therapy takes first step in healthy volunteers

NCT ID NCT07629310

Completed Knowledge-focused Sponsor: Jecho Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a single injection of JL18008, a lab-made protein designed to boost immune cells, in 40 healthy adults. The main goal was to check safety and how the body handles the drug. Researchers also measured changes in immune cell counts over 56 days. This is a first step toward possibly using JL18008 to help people with HIV who have low CD4+ T cells despite treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JL18008 (a lab-made protein that may boost immune cells)
What this could lead to: If safe, JL18008 could be tested in people with HIV to help raise their low CD4+ T cell counts, potentially improving immune function.
What could go wrong: This is a very early Phase 1 trial in only 40 healthy people. It only tests safety and dosing, not whether it works for HIV. Side effects or lack of effect in future studies are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.